Gilead Sciences (GILD) to acquire CymaBay Therapeutics (CBAY) in $4.3bn cash deal

February 12, 2024 8:55 AM EST Send to a Friend
Gilead Sciences (NASDAQ: GILD) announced on Monday that it would acquire CymaBay Therapeutics (NASDAQ: CBAY) for $4.3 billion. The purchase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login